RCEL$3.45
Chart
Performance
Key Stats
AI RCEL Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
HoldAVITA Medical shows potential in its niche therapeutic area, but recent financial performance and significant losses suggest caution. While the technology is innovative, the company's ability to achieve sustained profitability and manage its cash burn are key concerns. Investors should monitor earnings reports and regulatory approvals closely.
Thematic
AVITA Medical operates in the regenerative medicine and acute wound care market, a sector with growing demand driven by an aging population and increasing prevalence of chronic wounds. The RECELL System offers a unique approach to skin grafting.
Fundamental
AVITA Medical exhibits negative earnings and significant cash burn, raising concerns about profitability. While revenue is growing, the company is not yet profitable, and its financial position requires careful monitoring. The balance sheet shows substantial liabilities relative to equity.
Technical
The stock has experienced significant volatility and a strong downtrend over the past year, reflecting concerns about profitability and cash flow. While recent price action shows some stabilization, a clear bullish trend has not yet emerged. Trading activity shows mixed signals.
| Factor | Score |
|---|---|
| Regenerative Medicine & Wound Care Demand | 85 |
| Technological Innovation (RECELL System) | 80 |
| Regulatory Landscape | 70 |
| Competition | 65 |
| Healthcare Reimbursement | 70 |
| Factor | Score |
|---|---|
| Valuation | 40 |
| Profitability | 10 |
| Growth | 70 |
| Balance Sheet Health | 25 |
| Cash Flow | 20 |
| Factor | Score |
|---|---|
| Trend Analysis | 30 |
| Momentum | 50 |
| Volume | 60 |
| Support & Resistance | 55 |
| Moving Averages | 45 |
AI Investing Checklist
Powered by LiveAIBullish Points (5)
Improving EPS Trend
While recent EPS has been negative, the surprise percentage has shown improvement from Q2 2024 (-54.27%) to Q1 2025 (-37.66%), indicating a narrowing miss on estimates.
Revenue Growth Potential
The company has demonstrated consistent revenue growth, with revenue increasing from $34.42M in 2022 to $64.25M in 2024. The P/S ratio is within a reasonable range compared to historical data.
Bearish Points (7)
Consistent EPS Misses
The company has consistently missed EPS estimates across multiple quarters (e.g., Q4 2024, Q3 2024, Q2 2024), with significant negative surprises, indicating challenges in meeting profit expectations.
Negative Earnings and PE Ratio
The company has reported negative net income and EPS for the trailing twelve months and recent years. The Price-to-Earnings (P/E) ratio is not applicable or negative, reflecting unprofitability.
Calendar
August 2025
7
Next Earnings Date
H: $-0.24
A: $-0.36
L: $-0.48
H: 35.81M
A: 34.27M
L: 32.86M
Profile
AVITA Medical, Inc., together with its subsidiaries, operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds and full-thickness skin defects, as well as for repigmentation of stable depigmented vitiligo lesions. It also provides RECALL autologous cell harvesting device, which can treat areas of up to 1,920 cm2; RECELL autologous cell harvesting device with ease-of-use, an enhanced ease-of-use device that can treat areas of up to 1,920 cm²; and RECELL GO mini autologous cell harvesting device, a line extension of the RECELL GO system to treat smaller wounds up to 480 cm2, as well as RECELL GO autologous cell harvesting device consisting of RECELL GO processing device, which controls and manages the pressure applied to disaggregate the donor skin cells and controls the incubation time of the RECELL Enzyme to optimize cell yield and promote cell viability; and RECELL GO preparation kit, which can treat areas up to 1,920 cm2. In addition, the company markets, sells, and distributes PermeaDerm, a biosynthetic wound matrix; and Cohealyx, a collagen-based dermal matrix. It serves hospitals, treatment centers, and distributors. The company was formerly known as AVITA Therapeutics, Inc. and changed its name to AVITA Medical, Inc. in December 2020. AVITA Medical, Inc. is headquartered in Valencia, California.
Seasonals
Price Target
17.06 USD
The 39 analysts offering 1 year price forecasts for RCEL have a max estimate of 19.45 and a min estimate of 12.58.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 95
Direct competitor and peer in allogeneic cell therapy, with a focus on orthopedic indications (e.g., chronic low back pain, knee osteoarthritis) using mesenchymal stem cells, similar to Vericel's regenerative approach.
Weight: 90
Specializes in placental cell therapy (PLX cells) for regenerative medicine, including potential applications in muscle regeneration, bone repair, and orthopedic injuries, aligning closely with Vericel's core focus.
Weight: 88
A leader in placental and amniotic tissue allografts for wound care and surgical applications, including orthopedics. Their focus on regenerative tissue products presents market overlap with Vericel.
Weight: 85
A gene therapy company utilizing AAV vectors to develop treatments for various genetic diseases. While different from cell therapy, both operate at the forefront of advanced biologics and share future potential in regenerative medicine.